iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

March 13, 2025

SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its fully subscribed Series B-2 financing of $3 million.

This investment will support iVeena’s pursuit of advancing their innovative pediatric myopia program. All IND-enabling studies are well underway supporting a targeted IND submission in H1-2025.

“We are pleased to welcome Dr. Jerry Hu to our Board as an independent director,” said President and Founder, Bala Ambati, M.D., Ph.D., MBA. “Dr. Hu is a world-renowned ophthalmologist who stands at the forefront of cutting-edge ophthalmic innovations bringing significant value to our long-term strategy.”

https://www.businesswire.com/news/home/20250205113508/en/iVeena-Secures-3-Million-in-Series-B-2-Financing-to-Accelerate-Development-of-IVMED-85-for-Myopia